Asensus Surgical Inc Revenue Growth Rates (ASXC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Asensus Surgical Inc   (NYSE: ASXC)
 

ASXC's Revenue Growth by Quarter and Year

Asensus Surgical Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ASXC Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.55
1st Quarter March 1.07
FY 2.62

ASXCs Annual Revenue
Asensus Surgical Inc 's Revenue in the fiscal year 2023 $ 8.58 millions
Asensus Surgical Inc 's Revenue in the fiscal year 2022 $ 7.09 millions
Asensus Surgical Inc 's Revenue in the fiscal year 2021 $ 8.23 millions
Asensus Surgical Inc 's Revenue in the fiscal year 2020 $ 3.18 millions
Asensus Surgical Inc 's Revenue in the fiscal year 2019 $ 8.53 millions




ASXC Revenue second quarter 2024 Y/Y Growth Comment
Asensus Surgical Inc reported Revenue rise of 53.27% year on year in the second quarter 2024, to $ 1.55 millions, this is lower than Asensus Surgical Inc 's recent average Revenue surge of 407.68%.

Looking into second quarter 2024 results within Medical Equipment & Supplies industry 20 other companies have achieved higher Revenue growth. While Asensus Surgical Inc ' s Revenue jump of 53.27% ranks overall at the positon no. 298 in the second quarter 2024.


ASXC Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 120.73 % -0.81 % 123.42 %
3rd Quarter September - -91.41 % -0.39 % 217.28 %
2nd Quarter June 53.27 % 2.02 % -10 % 66.67 %
1st Quarter March 9.18 % -8.41 % -48.56 % 246.67 %
FY   - 7.91 % -13.97 % -

Financial Statements
Asensus Surgical Inc 's second quarter 2024 Revenue $ 1.55 millions ASXC's Income Statement
Asensus Surgical Inc 's second quarter 2023 Revenue $ 1.01 millions Quarterly ASXC's Income Statement


ASXC Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 2368.18 % -3.91 % -3.5 %
3rd Quarter September - -78.22 % 158.59 % 133.64 %
2nd Quarter June 44.67 % 3.06 % -7.48 % -47.12 %
1st Quarter March -80.29 % -60.16 % -56.85 % 87.39 %
FY (Year on Year)   - 7.91 % -13.97 % -


Back to ASXC Growth rate Comparisons >> Back to ASXC Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #21
Healthcare Sector #109
Overall #298

Revenue Y/Y Growth Statistics
High Average Low
6311.32 % 407.68 % -100 %
(Dec 31 2017)   (Dec 31 2015)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #21
Healthcare Sector #109
Overall #298
Revenue Y/Y Growth Statistics
High Average Low
6311.32 % 407.68 % -100 %
(Dec 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Asensus Surgical Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
5933.33 % 296.05 % -100 %
(Sep 30 2013)  


ASXC's II. Quarter Q/Q Revenue Comment
Asensus Surgical Inc achieved in the II. Quarter 2024 below company average Revenue jump of 44.67% quarter on quarter, to $ 1.55 millions.

II. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.06% in the II. Quarter a year ago.

Within Medical Equipment & Supplies industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Asensus Surgical Inc 's Revenue growth quarter on quarter, overall rank is 280.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #7
Healthcare Sector #79
Overall #280
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #7
Healthcare Sector #79
Overall #280
Revenue Q/Q Growth Statistics
High Average Low
5933.33 % 296.05 % -100 %
(Sep 30 2013)  


ASXC's II. Quarter Q/Q Revenue Comment
Asensus Surgical Inc achieved in the II. Quarter 2024 below company average Revenue jump of 44.67% quarter on quarter, to $ 1.55 millions.

II. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.06% in the II. Quarter a year ago.

Within Medical Equipment & Supplies industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Asensus Surgical Inc 's Revenue growth quarter on quarter, overall rank is 280.


Asensus Surgical Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 8.27 $ 7.73 $ 7.63 $ 4.67 $ 7.01
Y / Y Revenue Growth (TTM) 17.92 % 10.4 % 7.72 % -34.26 % -1.36 %
Year on Year Revenue Growth Overall Ranking # 2240 # 2208 # 1907 # 391 # 239
Seqeuential Revenue Change (TTM) 7 % 1.19 % 63.57 % -33.42 % 0.19 %
Seq. Revenue Growth (TTM) Overall Ranking # 2074 # 1514 # 2218 # 2328 # 2862


Cumulative Revenue growth Comment
Although Asensus Surgical Inc 's Annual Revenue growth year on year were below company's average 39.34% , Revenue announced in the Jun 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.92% year on year, from 10.4% in Mar 31 2024.

In the Healthcare sector 357 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2208 to 2240.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 112
Healthcare Sector # 358
Overall # 2240

Revenue TTM Y/Y Growth Statistics
High Average Low
430.43 %
 39.34 %
-82.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 343
S&P 500 # 2074
Cumulative Revenue growth Comment
Although Asensus Surgical Inc 's Annual Revenue growth year on year were below company's average 39.34% , Revenue announced in the Jun 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.92% year on year, from 10.4% in Mar 31 2024.

In the Healthcare sector 357 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2208 to 2240.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 112
Healthcare Sector # 358
Overall # 2240

Revenue TTM Y/Y Growth Statistics
High Average Low
430.43 %
39.34 %
-82.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 112
Sector # 343
S&P 500 # 2074




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ASXC's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Cue Biopharma Inc 92.33%$ 92.330 millions
Arcellx Inc 91.47%$ 91.470 millions
Pmgc Holdings Inc 91.31%$ 91.311 millions
Curevac N v 88.34%$ 88.337 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Axsome Therapeutics Inc 86.65%$ 86.651 millions
Universal Biosensors Inc 86.62%$ 86.623 millions
Volitionrx Limited82.98%$ 82.977 millions
Innovative Eyewear Inc 81.65%$ 81.654 millions
Adma Biologics Inc 78.34%$ 78.343 millions
Metagenomi Therapeutics Inc 76.48%$ 76.484 millions
Ispecimen inc 76.21%$ 76.211 millions
Axim Biotechnologies Inc 76.04%$ 76.040 millions
Rosecliff Acquisition Corp I75.91%$ 75.912 millions
Castle Biosciences Inc 73.53%$ 73.525 millions
Electrocore Inc 72.88%$ 72.881 millions
Immucell Corporation71.84%$ 71.836 millions
Rxsight Inc 71.12%$ 71.122 millions
Senti Biosciences Holdings Inc 69.37%$ 69.370 millions
Evofem Biosciences Inc 69.24%$ 69.243 millions
Sintx Technologies Inc 69.09%$ 69.094 millions
Sunshine Biopharma Inc 67.30%$ 67.295 millions
Innoviva Inc 61.07%$ 61.070 millions
Trisalus Life Sciences Inc 59.67%$ 59.670 millions
Ataibeckley Inc 58.72%$ 58.721 millions
Procept Biorobotics Corporation58.54%$ 58.537 millions
Natera Inc 58.13%$ 58.127 millions
Provectus Biopharmaceuticals Inc 57.56%$ 57.556 millions
Ligand Pharmaceuticals Incorporated57.52%$ 57.517 millions
Beone Medicines Ltd 56.07%$ 56.072 millions


About Asensus Surgical Inc Revenue Growth Rates (ASXC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Asensus Surgical Inc (CIK 876378).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-24-026428
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Asensus Surgical Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.